HEALTH
Gilead plans to skip from Phase 1 to Phase 3 with once-yearly HIV prevention drug – Endpoints News
- Gilead plans to skip from Phase 1 to Phase 3 with once-yearly HIV prevention drug Endpoints News
- A once-yearly PrEP? Gilead’s lenacapavir shows promise as company plots phase 3 FiercePharma
- Gilead data suggest once-yearly shot of PrEP drug blocks HIV infection STAT
- First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet Yahoo Finance
- ‘Annual shot to prevent HIV proven safe’ Hindustan Times
Source link
